Catalyst Pharmaceuticals Reports Fourth Quarter and Full
Achieved Record 2022 Total Net Revenues of $214 Million, a 52% YoY Increase Achieved FIRDAPSE® Q4 2022 Net Product Revenues of $61 Million, a 59% YoY...
Source: globenewswire.com
📰 Dydo Pharma News
Page 2 - Dydo Pharma News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Dydo Pharma. Real-time updates on events, politics, business and more.
Catalyst Pharmaceuticals Inc. (CPRX) is primed for evolution with the beta value of 1.30
For the readers interested in the stock health of Catalyst Pharmaceuticals Inc. (CPRX). It is currently valued at $7.18. When the transactions were called off in the previous session, Stock hit the highs of $7.21, after setting-off with the price of $6.99. Company’s stock value dipped to $6.925 du
Warren Buffett Dydo Pharma Catalyst Pharmaceuticals Inc Catalyst Pharmaceuticals Announces Dydo Pharma Initiation Catalyst Pharmaceuticals Stocks Primed
Source: investchronicle.com